Dianthus Therapeutics | MGTA - Sales Revenues

Stock Price
78.80
Daily Change
-0.10 -0.13%
Monthly
58.49%
Yearly
282.71%
Q1 Forecast
75.51

Dianthus Therapeutics reported $396K in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Akebia Therapeutics USD 57.34M 10.84M Mar/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
Avita Medical AUD 17.61M 805K Dec/2025
Celltrion KRW 1.33T 0 Mar/2026
Cspc Pharmaceutical CNY 6.62B 358.95M Sep/2025
Deva Holding AS TRY 2.32B 418.58M Sep/2023
Dianthus Therapeutics USD 396K 203K Sep/2025
Divis Laboratories Ltd INR 26.04B 1.11B Dec/2025
IQVIA Holdings USD 4.36B 260M Dec/2025
Kangmei Pharma CNY 1.37B 101.16M Sep/2025
Knight Therapeutics CAD 121.55M 14.19M Sep/2025
Laboratorios Farma EUR 448.66M 67.82M Dec/2023
Medical Developments International AUD 21.57M 12.04M Dec/2025
Moderna USD 678M 342M Dec/2025
Neuren Pharmaceuticals AUD 42.24M 28.1M Dec/2025
Organigram Holdings CAD 80.06M 9.27M Sep/2025
Organon & Co USD 1.51B 90M Dec/2025
Pharma Mar EUR 90.2M 54.5M Dec/2025
Qiagen NV USD 457.38M 6.06M Dec/2025
Revvity USD 772.06M 73.06M Dec/2025
Sartorius EUR 927.6M 84.4M Dec/2025
Sino Biopharmaceutical CNY 17.57B 4.58B Jun/2025
Tectonic Therapeutic USD 0 0 Dec/2024
Tilray USD 217.51M 74.75M Dec/2025
Viatris USD 3.7B 60M Dec/2025
Xeris Pharmaceuticals USD 74.38M 2.84M Sep/2025
Zhangzhou Pientzehuang Pharmaceutical CNY 2.88B 642.99M Sep/2025